Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

US12233059B2 · kind B2 · utility

Assignee

• Alto Neuroscience, Inc. · US

Inventors

• Amit Etkin · Palo Alto, US
• Wei Wu · Palo Alto, US
• Chao WANG · Los Altos, US
• Nicholas Cooper · Los Altos, US
• Joshua JORDAN · Brooklyn, US
• Adam Savitz · Greenwich, US

Key dates

• Filing date: May 21, 2024
• Grant date: Feb 25, 2025
• Expiry date: May 21, 2044

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61B5/374
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.